Sustiva

Sustiva, whose generic name is efavirenz, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) used in the treatment of HIV infection. It is a key component of combination antiretroviral therapy (ART) regimens, working synergistically with other antiretroviral agents to reduce viral load and improve immune function in people living with HIV. Sustiva has played a pivotal role in transforming HIV from a fatal illness into a manageable chronic condition.

The mechanism of action of Sustiva involves the inhibition of reverse transcriptase, an enzyme critical for the replication of HIV. By binding to and inactivating this enzyme, efavirenz prevents the conversion of viral RNA into DNA, thereby halting the replication cycle of the virus. This reduction in viral replication helps to decrease the overall viral load, allowing the patient's immune system to recover and function more effectively.

Sustiva is typically administered orally, usually once daily, due to its long half‑life and sustained activity. It is most commonly taken at bedtime, as it may cause central nervous system side effects such as dizziness or vivid dreams, which are less disruptive when the patient is sleeping. Adherence to the dosing schedule is crucial for maintaining effective viral suppression and preventing the development of drug resistance.

While Sustiva is generally effective, it is associated with several potential side effects. Common adverse effects include dizziness, insomnia, and vivid dreams, as well as potential rash or gastrointestinal disturbances. In some cases, more serious neuropsychiatric symptoms can occur, requiring dose adjustments or a change in therapy. Regular follow‑up and communication with healthcare providers are essential to manage these side effects and optimize treatment outcomes.

Overall, Sustiva represents an essential component of modern HIV therapy. Its ability to significantly reduce viral replication has been instrumental in improving the prognosis and quality of life for patients living with HIV. With careful adherence, monitoring, and supportive care, Sustiva, as part of a combination ART regimen, can help maintain viral suppression and promote long‑term health in individuals with HIV.


NOTE: The above information is for marketing purposes only and is not to be construed as medical advice. Seek advice for medications from a qualified physician.